ALS News Today

ALS News Today is a daily online news platform dedicated to keeping ALS patients and their caregivers informed about the newest scientific research and advancements related to the disease. Despite ongoing research and development efforts in ALS treatment, health media often overlooks this important information. To address this gap, ALS News Today employs a skilled team of researchers and journalists who gather the latest news on ALS and present it in an accessible way for patients.

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#668384

United States

#217201

Health/Health Conditions and Concerns

#563

Traffic sources

Monthly visitors

Articles

Usnoflast well tolerated in ALS patients and shows signs of efficacy: Study

6 days ago | alsnewstoday.com | Andrea Lobo

An experimental oral treatment from Zydus Lifesciences was well tolerated at all tested doses and showed signs of slowing disease progression in people with amyotrophic lateral sclerosis (ALS). That’s according to findings from a proof-of-concept Phase 2a trial (NCT05981040) in India that tested Zydus’ usnoflast in 24 adults with ALS. The therapy achieved therapeutic levels in the spinal fluid in most participants.
9 out of 10 NurOwn-treated ALS patients surpass five years of survival

1 week ago | alsnewstoday.com | Marisa Wexler

Nine out of 10 people with amyotrophic lateral sclerosis (ALS) who received the experimental cell therapy NurOwn (debamestrocel) in an expanded access program (EAP) following a placebo-controlled Phase 3 trial survived for at least five years after the onset of their symptoms.
Psychiatric medications linked to increased ALS risk, worse outcomes

1 week ago | alsnewstoday.com | Margarida Maia

People prescribed common psychiatric medications had a higher risk of developing amyotrophic lateral sclerosis (ALS) and saw worse outcomes after a diagnosis, with shorter survival and faster functional decline, a study in Sweden finds. Taking anxiolytics for anxiety, hypnotics or sedatives to help sleep or induce calm, or antidepressants to treat depression were linked to as much as a 34% higher risk of being diagnosed with ALS.
Dazucorilant significantly extends survival in Phase 2 ALS trial

1 week ago | alsnewstoday.com | Marisa Wexler

Dazucorilant, an oral cortisol modulator being developed by Corcept Therapeutics, significantly improved survival among people with amyotrophic lateral sclerosis (ALS) in a Phase 2 clinical trial. Despite it failing to slow disease progression, the trial’s main goal, Corcept is now seeking guidance from U.S. and European regulators to determine the best path forward for its experimental therapy.
What I can't accept about ALS, despite years of processing it

2 weeks ago | alsnewstoday.com | Juliet Taylor

It was seven years ago this summer that I unwittingly and unwillingly became a part of the ALS community when my late husband, Jeff, began exhibiting foot drop and slurred speech, symptoms that were worrisome enough for us to seek medical answers. His relatively quick diagnosis of ALS that fall was unexpected and shocking. Learning that Jeff had a terminal illness amid the relative peace of our everyday lives shattered our plans and, perhaps just as painfully, the ability to dream about them.
Zydus' usnoflast wins FDA's fast track drug designation for treating ALS

2 weeks ago | alsnewstoday.com | Andrea Lobo

The U.S. Food and Drug Administration (FDA) has granted fast track status to usnoflast, Zydus Lifesciences’ experimental oral inhibitor, for treating amyotrophic lateral sclerosis (ALS). The designation is meant to accelerate the development and review of new therapies that address unmet medical needs in serious or life-threatening conditions, and makes Zydus eligible for more frequent meetings and discussions with the FDA throughout the drug development process.
Searching for wisdom in the woods as we navigate ALS

3 weeks ago | alsnewstoday.com | Kristin Neva

A few weeks ago, I visited the Paavola Wetlands Nature Area a few minutes from my home. A local group that meets monthly for prayer and reflection was at the preserve, and since they were in the neighborhood, I decided to stop by. I’d be able to get back quickly if my husband, Todd, who has ALS, needed my help. The leader of the group had printed out various reflections and asked for volunteers to read some of them.
Treatment with jacifusen shows benefits for some people with FUS-ALS

3 weeks ago | alsnewstoday.com | Marisa Wexler

Treatment with the experimental therapy jacifusen was generally well tolerated and appeared to slow or even reverse disease progression in some people with amyotrophic lateral sclerosis (ALS) caused by mutations in the FUS gene. That’s according to data from 12 people who received the therapy as part of an expanded access program. Data from these cases also indicate jacifusen decreased nerve damage.
Transposon's TPN-101 selected for testing in HEALEY ALS trial

3 weeks ago | alsnewstoday.com | Margarida Maia

Oral small molecule TPN-101 has been selected for testing in amyotrophic lateral sclerosis (ALS) as part of the HEALEY ALS platform trial. The decision to include TPN-101 in the platform trial (NCT04297683) was based on the treatment’s unique mechanism of action and final data from a Phase 2 clinical trial (NCT04993755) in adults with ALS or frontotemporal dementia (FTD) related to C9orf72 mutations, developer Transposon Therapeutics said.
Adapting helped us keep the outdoors a part of life with ALS

1 month ago | alsnewstoday.com | Juliet Taylor

My late husband, Jeff, and I shared a love of the outdoors, even though our preferred activities were often different. I loved to hike and kayak, while Jeff, who’d been injured when a car hit his bicycle in 2010 and still suffered from orthopedic pain, preferred to relax. Whether at home or traveling, many evenings found him outside with a cigar, a beer, and music playing quietly on a portable speaker.